<DOC>
	<DOCNO>NCT01602952</DOCNO>
	<brief_summary>A Phase I/II multicenter study IY5511HCl Philadelphia chromosome positive chronic myeloid leukemia patient without optimal response tolerance Bcr-Abl tyrosine kinase inhibitor ( Imatinib and/ Dasatinib , Nilotinib ) In study , The efficacy safety CML patient resistant intolerable imatinib Chronic Accelerated phase . Phase 1 1 . To investigate Maximum Tolerated Dose ( MTD ) Dose Limiting Toxicity ( DLT ) oral Radotinib HCl bid ( twice daily ) Philadelphia chromosome-positive CML subject resistant , suboptimal responsive , intolerant imatinib OR resistant intolerant least one second-generation target anticancer agent resistant , suboptimal responsive , intolerant imatinib simultaneously . Phase 2 1 . To investigate safety oral Radotinib HCl CML patient resistant intolerable imatinib chronic accelerate phase . 2 . To evaluate hematologic cytogenetic efficacy oral Radotinib HCl CML patient resistant intolerable imatinib chronic accelerate phase .</brief_summary>
	<brief_title>Philadelphia Chromosome Positive CML Patients Without Optimal Response Tolerance Bcr-Abl TKI</brief_title>
	<detailed_description>This study multi-center , open-label , Phase 1/2 clinical trial Radotinib HCl , target anticancer agent inhibit Bcr-Abl oncoprotein . It aim determine optimal therapeutic dose confirm safety efficacy Radotinib HCl . Phase 1 study begin St. Mary 's hospital Korea Phase 2 study ongoing 9 Korean site 7 site China , India Thailand take part Phase 2 . After determination safe proper therapeutic dose Phase 1 , Phase 2 begin continuously evaluate efficacy chronic accelerated phase . Before start Phase 2 trial , interim final report Phase 1 trial review Korean Food Drug Administration .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Phase I 1 . Age ≥ 18 year old 2 . Ph+ CML patient resistant chronic , accelerate , acute phase , suboptimal responsive , intolerant imatinib resistant intolerant least one secondgeneration target anticancer agent resistant , suboptimal responsive , intolerant imatinib simultaneously . 3. WHO Performance status ≤2 4 . Patients must follow laboratory value With normal liver renal function 5 . Patients receive interferon , anti cancer drug radiotherapy &gt; 1 week prior start study drug . Phase II 1 . Age ≥ 18 year old 2 . Ph+ CML patient chronic accelerated phase resistant intolerant Imatinib mesylate 3. WHO Performance status ≤2 4 . Patients must follow laboratory value With normal liver renal function 5 . Patients receive interferon , anti cancer drug radiotherapy &gt; 1 week prior start study drug . Phase I 1 . CNS infiltration 2 . Impaired cardiac function , include one following . LVEF &lt; 45 % determine MUGA scan echocardiogram Clinically significant rest bradycardia 3 . Severe GI disease may cause drug absorption problem study drug 4 . Use therapeutic Warfarin 5 . Acute chronic liver renal disease 6 . Other concurrent severe and/or uncontrolled medical condition 7 . Treatment hematopoietic colonystimulating growth factor ≤1 week prior start study drug . 8 . Patients currently receive treatment medication potential prolong QT interval 9 . Patients receive Imatinib , interferon , anti cancer drug chemotherapy ≤ 1 week 10 . Patients receive Nilotinib Dasatinib ≤4 week prior start study drug . 11 . Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy 12 . Patients pregnant breastfeed adult reproductive potential employ effective method birth control . 13 . Patients agree use birth control study 3 month follow study completion . 15 . HIV infection Phase II 1 . Blast phase CML 2 . CNS infiltration 3 . Impaired cardiac function , include one follow LVEF &lt; 45 % determine MUGA scan echocardiogram Use Cardiac pacemaker ST depression &gt; 1mm 2 lead and/or T wave inversion 2 contiguous lead Congenital long QT syndrome History , presence significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia QTcF &gt; 480 msec screen ECG Right bundle branch block + leave anterior hemiblock , Bifascicular block Angina pectoris 4 . Severe GI disease may cause drug absorption problem study 5 . Use therapeutic Warfarin 6 . Acute chronic liver renal disease 7 . Other concurrent severe and/or uncontrolled medical condition 8 . Treatment hematopoietic colonystimulating growth factor ≤1 week prior start study drug . 9 . Patients currently receive treatment medication potential prolong QT interval 10 . Patients receive Imatinib , interferon , anti cancer drug chemotherapy ≤ 1 week 11 . Patients receive wide field radiotherapy ≤4 week prior start study drug . 12 . Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy 13 . Patients pregnant breastfeed adult reproductive potential employ effective method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radotinib</keyword>
	<keyword>CML-CP , AP</keyword>
</DOC>